Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
Cancer Cell|December 29, 2023
Melanoma and microbiota: Current understanding and future directionsBertrand Routy, Tanisha Jackson, Laura Mählmann, et al.Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.Cell|April 7, 2023
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatmentMackenzie J Bender, Alex C McPherson, Catherine M Phelps, et al.The Journal of Clinical Investigation|March 22, 2022
Tim-3 mediates T cell trogocytosis to limit antitumor immunityOrnella Pagliano, Robert M Morrison, Joe-Marc Chauvin, et al.Nature Medicine|March 1, 2022
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1John A McCulloch, Diwakar Davar, Richard R Rodrigues, et al.Science (New York, N.Y.)|February 5, 2021
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patientsDiwakar Davar, Amiran K Dzutsev, John A McCulloch, et al.Biorxiv : the Preprint Server for Biology|February 20, 2025
CDKN2A Low cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistanceRaquel Buj, Aidan R Cole, Jeff Danielson, et al.Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2022
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, et al.Pageof 13